These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29153631)

  • 1. Human abuse potential of brivaracetam in healthy recreational central nervous system depressant users.
    Schoedel KA; Stockis A; Sellers EM
    Epilepsy Behav; 2018 Jan; 78():194-201. PubMed ID: 29153631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: A Phase I randomized controlled trial.
    Levy-Cooperman N; Schoedel KA; Chakraborty B; Blum D; Cheng H
    Epilepsy Behav; 2016 Aug; 61():63-71. PubMed ID: 27315134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Crossover Study Evaluating the Abuse Potential of the Antiepileptic Drug Lacosamide in Healthy Recreational Drug Users.
    Schoedel KA; Andreas JO; Doty P; Eckhardt K; Sellers EM
    J Clin Psychopharmacol; 2017 Dec; 37(6):675-683. PubMed ID: 28926353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
    Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
    Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
    Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interactions between brivaracetam and ethanol in healthy males.
    Kruithof AC; Watanabe S; Peeters PA; de Kam ML; Zuiker RG; Stevens J; van Gerven JM; Stockis A
    J Psychopharmacol; 2017 Jul; 31(7):915-926. PubMed ID: 27649776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users.
    Schippers F; Pesic M; Saunders R; Borkett K; Searle S; Webster L; Stoehr T
    J Clin Pharmacol; 2020 Sep; 60(9):1189-1197. PubMed ID: 32495449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study.
    Wilbraham D; Berg PH; Tsai M; Liffick E; Loo LS; Doty EG; Sellers E
    J Clin Pharmacol; 2020 Apr; 60(4):495-504. PubMed ID: 31745991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
    Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
    J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
    Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
    Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
    Trinka E; Tsong W; Toupin S; Patten A; Wilson K; Isojarvi J; James D
    Epilepsy Res; 2020 Oct; 166():106403. PubMed ID: 32673969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
    Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
    Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures.
    Schoemaker R; Wade JR; Stockis A
    Clin Pharmacokinet; 2018 Jul; 57(7):843-854. PubMed ID: 28884437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
    Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
    Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.
    Schoedel KA; Rolleri RL; Faulknor JY; Pixton GC; Chen N; Bass A; Sommerville KW; Sellers E
    J Opioid Manag; 2012; 8(5):315-27. PubMed ID: 23247908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
    Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
    CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.